AA
RNAM

Ancora Advisors’s Avidity Biosciences RNAM Stock Holding History

Ancora Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,000
Closed -$92.1K – 1891
2023
Q1 		$92.1K Buy
6,000
+3,000
+100% +$66K ﹤0.01% 781
2022
Q4 		$67K Hold
3,000
– – ﹤0.01% 904
2022
Q3 		$49K Hold
3,000
– – ﹤0.01% 1090
2022
Q2 		$44K Buy
+3,000
New +$44.6K ﹤0.01% 1210

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ancora Advisors's RNAM Position: Q2 2023 in Review

Ancora Advisors sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 6,000 shares — an estimated $92.1K sold.

Ancora Advisors first reported a position in RNAM in Q2 2022 and held it in 4 quarters. The position peaked at $92.1K in Q1 2023. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

  • Ancora Advisors reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
  • Ancora Advisors sold 6,000 Avidity Biosciences shares in Q2 2023, an estimated $92.1K.
  • Ancora Advisors first reported a position in Avidity Biosciences in Q2 2022 and held it in 4 quarters.
  • Ancora Advisors's Avidity Biosciences position peaked at $92.1K in Q1 2023.
  • 143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on Ancora Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.